Our Putnam PHMR colleagues delivered an in-depth analysis on the burden of patient hospitalizations in France as a result of COVID-19. The study population consisted of all patients hospitalized in 2020 – assessing healthcare resource consumption in the hospital setting through the French national health insurance claims database. The article is featured in the Journal of Market Access & Health Policy.
Background: The economic consequences of the recent COVID-19 pandemic were substantial. However, direct medical costs in France have not been determined
Objective: To describe patient characteristics, intensity of care, mortality, and direct medical costs in patients hospitalized for COVID-19 infections in France
Study design: A retrospective study of the French national hospital claims database for 2020
Setting: Hospital care
Patients or other participants: All patients hospitalized for COVID-19 in 2020 were included and classified by hospitalization duration into acute phase and prolonged COVID-19
Intervention: Stratification by intensity of care (Level 1: no or low-flow oxygen support; Level 2: non-invasive ventilation; Level 3: mechanical ventilation)
Main outcome measure: Cost of hospital care in 2020 Euros from a payer perspective
Results: 199,455 patients were hospitalized for COVID-19 in France in 2020. 17,824 patients (8.9%) received mechanical ventilation and 32,602 patients (16.3%) died. Mean per patient cost was €5,510 ± 7,142. This cost was highest in patients receiving Level 3 care, patients aged >80 years and in those with prolonged COVID
Conclusion: The economic burden of hospitalizations for COVID-19 infections in France during 2020 was substantial. The study provides robust baseline data to benchmark advances in the standard of care and to nurture epidemiological models
Jump to a slide with the slide dots.
Discover how Medical Affairs can shift from activity metrics to impact-driven strategies with AI and analytics. Read the full report.
Read moreDiscover how to select the right preference method DCE, BWS, MDT or OPUF for rare diseases and small sample studies.
Read moreExplore a new model for antibiotic investment—driven by AMR, evolving P&R frameworks, and key indicators shaping commercial strategy.
Read more